Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated at Guggenheim

Guggenheim began coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a report published on Monday morning, MarketBeat.com reports. The firm issued a buy rating and a $12.00 price objective on the stock.

CMPX has been the subject of several other research reports. Piper Sandler started coverage on shares of Compass Therapeutics in a research note on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Leerink Partnrs lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. D. Boral Capital reaffirmed a “buy” rating and issued a $32.00 target price on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Finally, Leerink Partners lowered Compass Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $5.00 to $4.00 in a research note on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Compass Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $11.38.

Compass Therapeutics Stock Performance

Shares of NASDAQ CMPX opened at $2.97 on Monday. The company’s 50-day moving average price is $2.52 and its 200 day moving average price is $1.92. Compass Therapeutics has a 52 week low of $0.76 and a 52 week high of $4.08. The stock has a market cap of $408.64 million, a price-to-earnings ratio of -8.03 and a beta of 1.17.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CMPX. Squarepoint Ops LLC acquired a new position in shares of Compass Therapeutics during the 4th quarter valued at $35,000. Tang Capital Management LLC boosted its stake in Compass Therapeutics by 225.4% during the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock valued at $8,555,000 after buying an additional 4,087,005 shares in the last quarter. ProShare Advisors LLC grew its holdings in Compass Therapeutics by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock worth $42,000 after acquiring an additional 9,451 shares during the period. MPM Bioimpact LLC raised its position in Compass Therapeutics by 51.9% in the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock worth $12,423,000 after acquiring an additional 2,926,002 shares in the last quarter. Finally, Enavate Sciences GP LLC acquired a new stake in Compass Therapeutics in the 4th quarter valued at about $11,293,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.